Fred Hutchinson Cancer Center treats the full range of cancers that can affect endocrine glands, including your parathyroid glands. Our endocrine tumor experts are UW Medicine physicians who also see ...

September 19, 2007--Cinacalcet ( Sensipar, Amgen) may emerge as an important new therapeutic option for patients with inoperable parathyroid carcinoma, researchers report. According to the results of ...

Norman Parathyroid Center, Clayman Thyroid Center, and Carling Adrenal Center Expand Their Lead as the World’s ...

A newly-created prognostic tool reliably predicts the recurrence of parathyroid cancer, enabling physicians to identify patients at the highest risk. Consequently, the tool also helps to determine the ...

At Fred Hutchinson Cancer Center, we surround you with experts who focus completely on cancer, day in and day out. A handful of people form the core of your care team. You have an oncologist who ...

New research reveals that the drug cinacalcet HCl (cinacalcet) may effectively reduce the dangerous accumulation of calcium in the blood that typically accompanies parathyroid cancer. This drug ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Phase I dose escalation study of pan-histone deacetylase (HDAC) inhibitor abexinostat in combination with cisplatin in patients with advanced non-keratinizing nasopharyngeal carcinoma. E1308: ...

The survival of patients with parathyroid cancer is often fairly long, especially if the initial operation is carried out at a specialized endocrine surgery center, shows a new retrospective study.

Background A 54-year-old man presented to the emergency department of his local hospital with a 1-year history of fatigue, weight loss, and constipation. He had abused alcohol for many years, and his ...

Third party assessment of resection margin status in head and neck cancer. Role of endothelial-specific growth-factors in efficacy of cetuximab in pts with head and neck squamous cell carcinoma (HNSCC ...